{"id":651386,"date":"2023-05-15T15:44:01","date_gmt":"2023-05-15T15:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=651386"},"modified":"2023-05-15T15:44:01","modified_gmt":"2023-05-15T15:44:01","slug":"nonradiographic-axial-spondyloarthritis-nraxspa-market-size-and-share-epidemiology-and-competitive-landscape-2032-companies-novartis-pharmaceuticals-ucb-biopharma-galapagos-nv","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonradiographic-axial-spondyloarthritis-nraxspa-market-size-and-share-epidemiology-and-competitive-landscape-2032-companies-novartis-pharmaceuticals-ucb-biopharma-galapagos-nv_651386.html","title":{"rendered":"Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Size and Share, Epidemiology and Competitive Landscape 2032 | Companies &#8211; Novartis Pharmaceuticals, UCB Biopharma, Galapagos NV"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1684124270.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Size and Share, Epidemiology and Competitive Landscape 2032 | Companies - Novartis Pharmaceuticals, UCB Biopharma, Galapagos NV\" src=\"https:\/\/www.abnewswire.com\/uploads\/1684124270.jpeg\" alt=\"Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Size and Share, Epidemiology and Competitive Landscape 2032 | Companies - Novartis Pharmaceuticals, UCB Biopharma, Galapagos NV\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Non-Radiographic Axial Spondyloarthritis Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) &#8211; Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA), historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight launched a new report on &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-radiographic-axial-spondyloarthritis-nraxspa-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2032<\/a>.&rdquo;<\/p>\n<p style=\"text-align: justify;\">Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) is a different kind of inflammatory arthritis. It falls under an umbrella category of diseases called spondyloarthritis, which includes different types of arthritis with one distinguishing feature. There is almost always inflammation in the spine.<\/p>\n<p style=\"text-align: justify;\">Back pain is &ldquo;the hallmark of Non-Radiographic Axial Spondyloarthritis, which sets it apart from any other type of inflammatory arthritis. &ldquo;Non-radiographic&rdquo; means the disease causes symptoms, but there is no visible damage on X-rays, the way there is with a related type of inflammatory arthritis called ankylosing spondylitis.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-radiographic-axial-spondyloarthritis-nraxspa-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Report 2032<\/a>&ldquo; delivers an in-depth understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA), historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a detailed sample copy of the report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-radiographic-axial-spondyloarthritis-nraxspa-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/non-radiographic-axial-spondyloarthritis-nr-axspa-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Non-Radiographic Axial Spondyloarthritis Symptoms:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pain and stiffness in the back or buttocks.<\/li>\n<li>Pain that worsens after rest (for example, after waking up) and is relieved by exercise.<\/li>\n<li>Pain in tendons (which connect muscles to bones) and ligaments (which connect bones), often felt as pain at the front of the chest, back of the heel or underneath the foot.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&ldquo;The prevalence of human leukocyte antigen B27 (HLA-B27) was similar for nr-axSpA and AS which is 86.4% for nr-axSpA vs. 89.1% for AS, 74.7% for nr-axSpA vs. 82.2% for AS, and 74.8% for nr-axSpA vs. 81.5% AS.&rdquo;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Non-Radiographic Axial Spondyloarthritis Key pharma players involved:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis Pharmaceuticals<\/li>\n<li>UCB Biopharma<\/li>\n<li>Galapagos NV<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Click here and request free sample pages for our <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-radiographic-axial-spondyloarthritis-nraxspa-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Non-Radiographic Axial Spondyloarthritis Market Outlook 2032<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Key Insight<\/p>\n<p style=\"text-align: justify;\">2 Executive Summary of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)<\/p>\n<p style=\"text-align: justify;\">3 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4 Disease Background and Overview: Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)<\/p>\n<p style=\"text-align: justify;\">5 Case Reports<\/p>\n<p style=\"text-align: justify;\">6 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7 United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">8 EU5 Epidemiology<\/p>\n<p style=\"text-align: justify;\">9 Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">10 Current Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">11 Unmet needs<\/p>\n<p style=\"text-align: justify;\">12 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">13 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">14 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) 7MM Market Analysis<\/p>\n<p style=\"text-align: justify;\">15 United States<\/p>\n<p style=\"text-align: justify;\">16 EU-5 countries: Market Outlook<\/p>\n<p style=\"text-align: justify;\">17 Japan Market Outlook<\/p>\n<p style=\"text-align: justify;\">18 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Drivers<\/p>\n<p style=\"text-align: justify;\">19 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Barriers<\/p>\n<p style=\"text-align: justify;\">20 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">21 Reimbursement and market access<\/p>\n<p style=\"text-align: justify;\">22 Appendix<\/p>\n<p style=\"text-align: justify;\">23 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">24 Disclaimer<\/p>\n<p style=\"text-align: justify;\">25 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>View our detailed report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-radiographic-axial-spondyloarthritis-nraxspa-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/non-radiographic-axial-spondyloarthritis-nr-axspa-market<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=nonradiographic-axial-spondyloarthritis-nraxspa-market-size-and-share-epidemiology-and-competitive-landscape-2032-companies-novartis-pharmaceuticals-ucb-biopharma-galapagos-nv\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=nonradiographic-axial-spondyloarthritis-nraxspa-market-size-and-share-epidemiology-and-competitive-landscape-2032-companies-novartis-pharmaceuticals-ucb-biopharma-galapagos-nv\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Non-Radiographic Axial Spondyloarthritis Market DelveInsight&#8217;s &#8220;Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) &#8211; Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA), historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/nonradiographic-axial-spondyloarthritis-nraxspa-market-size-and-share-epidemiology-and-competitive-landscape-2032-companies-novartis-pharmaceuticals-ucb-biopharma-galapagos-nv_651386.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-651386","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=651386"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=651386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=651386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=651386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}